Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
Phase 2
23
about 2 years
18+
1 site in CA
Why this study is shown
What this study is about
This trial is testing a treatment with Sacituzumab Govitecan and Nivolumab for people who have muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract. The goal is to see if this combination helps prevent cancer from coming back after surgery.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Nivolumab
- 2.Take Sacituzumab Govitecan (SG)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), sacituzumab govitecan
infusion
Primary: Primary Objective
Oncology